Intellia Therapeutics, Inc.
NTLA
$13.39
-$0.09-0.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 20.49% | 14.64% | 5.62% | -8.32% | -7.86% |
| Total Depreciation and Amortization | 54.82% | 22.47% | 2.83% | 8.83% | 14.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -48.78% | -33.37% | -13.34% | 34.29% | 13.32% |
| Change in Net Operating Assets | -720.91% | -657.66% | -524.05% | 62.06% | 122.65% |
| Cash from Operations | -13.14% | -15.11% | -12.14% | 6.97% | 11.47% |
| Capital Expenditure | 80.46% | 68.59% | 65.49% | 68.35% | 58.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 74.47% | 1,248.34% | 198.94% | 99.16% | 856.51% |
| Cash from Investing | 81.60% | 1,665.52% | 222.07% | 121.06% | 500.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -29.21% | -54.53% | -56.28% | -33.14% | 42.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -29.21% | -54.53% | -56.28% | -33.14% | 42.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.25% | 256.22% | 165.31% | 68.97% | 87.27% |